Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).

@article{Ishida2004PhaseIS,
  title={Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).},
  author={Kaoru Ishida and Nobutoshi Ando and Seiichiro Yamamoto and Hiroko Ide and Masayuki Shinoda},
  journal={Japanese journal of clinical oncology},
  year={2004},
  volume={34 10},
  pages={615-9}
}
BACKGROUND In Japan, concurrent chemoradiotherapy is the standard treatment for unresectable esophageal cancer. The optimal combination of chemotherapeutic agents and radiotherapy dose remains controversial. The present study consists of a phase II trial of a cisplatin (CDDP)/5-fluorouracil (5-FU) infusion with concurrent radiotherapy in patients with unresectable, advanced esophageal cancer. METHODS Between March 13, 1996, and April 28, 1998, 60 patients with advanced squamous cell carcinoma… CONTINUE READING